Bilastine is a state-of-the-art second-generation antihistamine featuring a unique benzimidazole backbone. It binds with extreme selectivity to peripheral H1 receptors, showing no measurable affinity for muscarinic, serotonergic, or adrenergic receptor pathways. This targeted mechanism prevents typical antihistamine side effects like dry mouth or urinary retention. It stabilizes peripheral tissue barriers against sudden histamine releases, offers a highly durable 24-hour therapeutic window, and is completely non-metabolized by the liver, passing through the system unchanged to offer stable pharmacokinetics with an exceptional safety index.